Does Clostridium butyricum reduce in-hospital mortality?
The user asks whether Clostridium butyricum as a probiotic lowers the risk of dying in hospital. The assistant explains that no direct evidence exists for mortality reduction; studied outcomes include reduced inflammation and fever duration, but research is limited to single studies per outcome.
Does taking Clostridium butyricum as a probiotic actually help lower the risk of dying while in the hospital?
To answer your question directly: Based on the available research data, there is no direct evidence that Clostridium butyricum lowers the risk of dying while in the hospital.
Here's what we know from Pillser's research database:
Clostridium butyricum has been studied for 10 health outcomes, including some that could theoretically be relevant in a hospital setting — such as:
- Reduced inflammation (1 study, beneficial)
- Reduced fever duration (1 study, beneficial)
- Reduced Clostridium difficile cytotoxicity (1 study, beneficial)
- Improved gut microbiota composition (1 study, beneficial)
- Reduced bacteremia (1 study, neutral — not beneficial, not harmful)
However, none of the studied outcomes specifically address in-hospital mortality risk1. The research on this probiotic is still quite limited (only 1 study per outcome), and mortality reduction was not among the endpoints studied.
That said, some of these effects — such as reducing inflammation, fever duration, and C. difficile cytotoxicity — could theoretically contribute to better outcomes in hospitalized patients, but this is speculative and not supported by direct evidence at this time.
If you're interested in specific probiotics with more evidence for hospital-related outcomes, I'd be happy to help you explore that.
Footnotes
-
Pillser research database, Clostridium butyricum. ↩